Laboratory for next-generation T cell therapies

Our laboratory focuses on the development of cell-based therapies for non-oncological diseases.  We are primarily interested on precision gene editing and redirecting human effector and regulatory T cells specificities using CRISPR-Cas9-based technologies. Specifically, we aim to:

• Develop Regulatory T cell therapy for Celiac diseases
• Develop Regulatory T cell therapy for allergic diseases
• To understand the role of CD28-CAR heterodimer and improve the safety of CAR-T cell therapy
• To develop novel anti-HIV cell-based therapies

Our group uses CRISPR-Cas9 technologies in combination with AAV to redirect the specificities of human lymphocytes. We are identifying and developing novel TCR and CAR using single-cell transcriptomic methodologies from the peripheral blood of patients we follow in our clinic.